On June 14, 2017, Pfizer (PFE) announced an agreement with Basilea Pharmaceutica for exclusive commercial rights for Cresemba in Europe.
On June 16, 2017, Pfizer announced detailed results from its ORAL (Oral Rheumatoid Arthritis TriaL) Strategy.
Pfizer (PFE) has started a Phase 1 clinical trial to evaluate an investigational vaccine for protection against Group B streptococcus in infants younger than three months.
On June 16, 2017, a German court awarded “co-entitlement” rights to Edwards Lifesciences’ (EW) subsidiary CardiAQ valve to the Tiara European patent application of Neovasc.
On June 5, 2017, Edwards Lifesciences (EW) received FDA approval for its Sapien 3 transcatheter heart valve for aortic and mitral valve-in-valve procedures.
Edwards Lifesciences (EW) is one of the leading players in the artificial valve market. After falling toward the end of 2016, EW stock has recovered recently and returned ~26.5% year-to-date.
Intuitive Surgical (ISRG) has returned approximately 48.2% YTD (year-to-date), surpassing SPY as well as the Health Care Select Sector SPDR Fund (XLV) by enormous margins.
Intuitive Surgical (ISRG) has witnessed a recent rally, and it reached an all-time high of $940.4 on June 20, 2017.
On May 30, 2017, Intuitive Surgical (ISRG) announced that it received FDA (US Food and Drug Administration) approval of its new da Vinci X robotic surgical system.
Intuitive Surgical’s da Vinci Sp is the latest technological innovation in the company’s surgical systems.
In March 2017, Vertex Pharmaceuticals (VRTX) announced promising results from two phase-3 clinical trials, Evolve and Expand.
Vertex (VRTX) has planned to submit a new drug application to the FDA in 3Q17 for a Tezacaftor-Ivacaftor combination treatment for cystic fibrosis.
In 2016, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $979 million, reflecting ~180% YoY (year-over-year) growth.
In 2016, Vertex Pharmaceuticals’ (VRTX) Kalydeco reported revenues of around $703 million, which represents ~11% growth on a YoY (year-over-year) basis.
In 2016, Vertex Pharmaceuticals (VRTX) reported revenues of around ~$1.7 billion, which reflected a whopping 65% YoY (year-over-year) growth.
Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.
In 2016, Celgene’s (CELG) Otezla generated revenues of around $1.0 billion, a 116% year-over-year (or YoY) increase.
Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.
In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).
In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.